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Cell deathal of degradative enzymes are increasingly becoming an area of interest in the
ﬁeld of oncology. The changes induced in this compartment upon transformation are numerous and whereas
most are viewed as pro-oncogenic the same processes also render cancer cells susceptible to lysosomal death
pathways. This review will provide an overview of the pro- and anti-oncogenic potential of this compartment
and how these might be exploited for cancer therapy, with special focus on lysosomal death pathways.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionSince the discovery of lysosomes by de Duve in 1955[1] this
organelle has been mainly viewed as a ﬁnal destination for endocytic
cargo and macromolecules destined for breakdown. This view of the
lysosomes as, at best, a garbage disposal unit, and at worst, an
unspeciﬁc “suicide bag” has changed dramatically due to recent
discoveries that provide evidence for numerousmore speciﬁc tasks for
lysosomes and their contents.
As the main compartment for intracellular degradation and
subsequent recycling of cellular constituents, the lysosomes receive
both hetero- and autophagic cargo, which in the degradative lumen of
this organelle ﬁnd their ﬁnal destination. The degradation is carried
out by a number of acid hydrolases (phosphatases, nucleases,
glycosidases, proteases, peptidases, sulfatases, lipases, etc) capable
of digesting all major cellular macromolecules [2]. The best-studied
lysosomal hydrolases are the cathepsin proteases which can be
divided into three sub-groups according to their active site amino acid,
i.e. cysteine (B, C, H, F, K, L, O, S, V,Wand X/Z), aspartate (D and E) and
serine (G) cathepsins [3].
Until recently the function of lysosomes and their cathepsins was
thought to be limited to intralysosomal protein-turnover, and the
degradation of the extracellularmatrixonce secreted. However, during
the past few years many of the cathepsins have been accredited with
more speciﬁc functions including roles in bone remodeling, antigen
presentation, epidermal homeostasis, prohormone processing,
maintenance of the central nervous system in mice, angiogenesis,
cell death and cancer cell invasion [4–8]. Importantly, cancer cellsll rights reserved.show transformation-induced changes of the lysosomal compartment
which have pro-oncogenic effects when lysosomal hydrolases parti-
cipate in tumor growth, migration, invasion and angiogenesis [9] (Fig.
1). Simultaneously, however, the very same changes in the lysosomal
compartment may sensitize cells to the lysosomal death pathway,
hereby allowing cell death to occur even in cancer cells with multiple
defects in the classical apoptosis signaling pathways [10].
This review will seek to offer a detailed view of how the pro- and
anti-oncogenic potential of this degradative compartment can be
exploited to the beneﬁt of the cancer patient, with emphasis on
lysosomal induced cell death.
2. Lysosomes and cancer cell death
Regulation of overall cell number as well as the amount of cells
constituting the different tissues along with the need for a mechanism
of eliminating unwanted cells is of fundamental importance in
multicellular organisms [11]. Apoptosis is the primary means to this
end, endowing the multicellular organism with the potential to rid
itself of unwanted cells without the leakage of cellular constituents,
thus avoiding the inﬂammation associated with necrosis, the
conceptual counterpart to programmed cell death. A recurrent
theme in the development of cancers is the development of defects
in the complex pathways controlling programmed cell death [10].
Cancer cells often harbor mutations in pro-apoptotic proteins (e.g.
Bax, Apaf-1 and p53) and can also rely on the overexpression of anti-
apoptotic proteins (e.g. Bcl-2, Bcl-xL, Akt/PKB and inhibitors of
apoptotic proteins) as a means to protect them from cell death. As
such, cancer cells have a number of opportunities to block classical
apoptotic pathways and interfere with efﬁcient caspase activation
[10]. Fortunately several lines of evidence suggest that although
Fig. 1. Lysosomal involvement in cancer. Lysosomes and their enzymes serve multiple roles in cancer depending on the context. An example is the case of release of cysteine
cathepsins; if released intracellularly they can contribute to the demise of the cancer cell; if released extracellularly they can act pro-oncogenic in breaking down the extracellular
matrix, stimulating angiogenesis and migration. Other roles for lysosomes in cancer include their role as a degradative compartment in the turnover of macromolecules;
downregulation of signaling from receptor tyrosine kinases as e.g. the EGFR as well as being the ﬁnal station in the autophagic pathway. RTK: Receptor tyrosine kinase, EGFR:
Epidermal growth factor receptor.
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death can still occur through the release of lysosomal enzymes.
Importantly, the lysosomal cell death pathway can be efﬁciently
triggered by many conventional chemotherapeutic regimens (Table 1
and references herein).
The appreciation of a regulated lysosomal involvement in cell
death began within the past decade where the exclusive role of
caspases as the executioners of cell death was challenged [12–15].
As newly developed caspase-speciﬁc pharmacological inhibitors as
well as inactivation of caspase-pathways by different factors [10,16,17]
did not always stop the progression towards death, they revealed, or
even enhanced, a subset of underlying caspase-independent death
programs. These programs include death-receptor initiated pathways
[10,18,19] as well as pathways elicited by cancer drugs, growth-factor
deprivation, staurosporine, Bax-related proteins and the depletion of
Hsp70[16,20–22]. The morphological features of these caspase-
independent death programs are often reminiscent of the ones
observed for classical apoptosis, and experimental support for a role
for other proteases such as cathepsins, calpains and serine proteases as
essential cofactors eitherupstreamordownstreamof caspases is rapidly
growing [14,23–28]. The argument is strengthened by the ﬁndings that
many non-caspase proteases are able to cleave at least some of the
classic caspase substrates, which might explain some of the similarities
observed between the caspase-dependent and -independent death
programs [14,27,29,30].
The discovery of lysosomal cell death pathways may have been
additionally delayed, because the lysosomal ultrastructure appears
intact in apoptotic cells analyzed by electron microscopy [31]. Thus,
the lysosomal rupture has until recently been considered as an all-or-
nothing switch during late stages of uncontrolled necrotic cell death
and tissue autolysis [32]. However, newer studies have revealed thatlysosomes with normal ultrastructure may have leaked part of their
enzymes, and that partial lysosomal membrane permeabilization
(LMP) not only occurs early in many death paradigms, but can in fact
trigger apoptosis and apoptosis-like cell death [8,27].
Although one can argue the relevance of such lysosomal death
programs, as they are masked by the efﬁcacy of the caspases, evidence
is gathering for an evolutionarily conserved role for lysosomal
cathepsin proteases in cell death programs initiated as a response to
various stimuli such as death receptors of the tumor necrosis factor
receptor family, hypoxia, oxidative stress, osmotic stress, heat and
anti-cancer drugs [15,31,33–35].
2.1. Evidence for lysosomes as cell death initiators
Evidence for the potential of lysosomes as programmed cell death
initiators come from studies with various compounds that directly
target the integrity of the lysosomal membranes. These have convin-
cingly proven that moderate lysosomal permeabilization can result in
programmed cell death [8,36–40]. A quantitative relationship
between the amount of lysosomal rupture and the mode of cell
death has been suggested to explain the widely different morpholo-
gical outcomes following LMP [41]. According to this model, low stress
intensities trigger a limited release of lysosomal contents to the
cytoplasm followed by apoptosis or apoptosis-like cell death, while
high intensity stresses lead to a generalized lysosomal rupture and
rapid cellular necrosis. Accordingly, low concentrations of sphingo-
sine, an acid ceramidase-generated metabolite of ceramide with
detergent-like properties at low pH, induces partial LMP and caspase-
mediated apoptosis, whereas higher concentrations result in massive
LMP and caspase-independent necrotic cell death. In this model, the
death triggered by partial LMP can be inhibited by pharmacological
Table 1
Lysosomal enzymes involved in cancer cell death
Lysosomal enzyme Cell type Stimulus Reference
Cathepsin B and L Immortalized and transformed murine embryonic ﬁbroblasts TNF-α [32]
MCF-7 human breast cancer Siramesine [94]
HeLa human cervix carcinoma, U-2-OS human osteosarcoma, MCF-7 LEDGF RNAi [22]
MCF-7, MDA-MB-468 human breast cancer Hsp70 antisense [91]
WEHI-S mouse ﬁbrosarcoma cells, ME-180 human cervix carcinoma TNF-α [91]
HeLa, MCF-7 Vincristine, vincristine+siramesine [40]
U937 human leukemia cells and Namalwa B human lymphoma cells Camptothecin [96]
Human non-small cell lung cancer Microtubule stabilizing agents [11]
MCF-7 TNF-α [81]
WEHI-S, ME-180 TNF-α [35]
Rat hepatoma cell line Bile salt [35]
Cathepsin D U937 Etoposide, TNF-α, TRAIL [29]
HeLa TNF-α, IFN-γ, anti-Fas [25]
HL-60 human leukemia Synthetic retinoid CD437 [126]
Jurkat human leukemia T cells Sphingosine [65]
Murine lymphoma cell line Induction of wild-type p53 [127]
Acid sphingomyelinase Human glioma cells Anti-Fas [107]
Human glioma cells γ-radiation [47]
HT-29 Human colorectal cancer TNF-α [21]
Acid ceramidase Ewings sarcoma cells Fenretinide [6]
Human glioma cells γ-radiation [47]
Not identiﬁed HeLa L-leucyl-l-leucine methyl ester [20]
1c1c7 murine hepatoma Photodynamic therapy [16]
HeLa Cipro-/Norﬂoxacin+UV light [10]
Jurkat human leukemia T cells α-tocopherol succinate [89]
Jurkat human leukemia T cells Anti-Fas, oxidative stress, growth factor starvation [15]
Human glioblastoma and gastric cancer Oncogenic Ras expression [19]
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cytosolic cathepsin activity precedes the activation of caspases and
mitochondrial membrane potential changes suggesting a direct role
for cytosolic cathepsins in the death process. Importantly, the role of
LMP and cathepsins in cell death is not limited to the experimental
models employing direct lysosomal disrupters. LMP also participates
in the execution of cell death in response to a wide variety of classic
apoptotic stimuli, such as activation of death receptors of tumor
necrosis factor (TNF) receptor family [23,26,42,43], interleukin-1[44],
p53 activation [45], growth factor starvation [42], microtubule
stabilizing agents [46], etoposide [10,40], sigma-2 receptor activation
[47], synthetic retinoid CD437[48], B cell receptor activation [49,50],
staurosporine [51], osmotic stress [33], as well as small molecules
identiﬁed in a screen for novel anti-cancer drugs that induce p53
independent apoptosis [52].
Interestingly, studies employing immortalized murine embryonic
ﬁbroblasts (MEFs) from mice deﬁcient for individual cathepsins have
clearly revealed that different cathepsins are crucial components in
cell death programmes, although their mutual importance varies
depending on the stimulus triggering LMP [53]. Immortalized MEFs
from cathepsin B and L deﬁcient mice, but not from cathepsin D
deﬁcient mice, are e.g. highly resistant to TNF, whereas the opposite
picture emerges when the cells are treated with staurosporine.
Extensive studies on TNF-induced cell death pathways have further
revealed that the role of individual cathepsins in cell death depends
on the cell type studied as exempliﬁed by cathepsin D depletionwhich
effectively protects HeLa cervix cancer cells against TNF- and cisplatin-
induced cytotoxicity [25,54]. This difference does not appear to be due
to general differences between human and murine cells, because
cathepsin B alone or together with other cysteine cathepsins is also
crucial for the effective TNF-induced killing in human cervix (ME-180)
and breast (MCF-7) cancer cell lines [23]. The explanation for this
diversity is as yet unknown, but varying expression levels of individual
cathepsins and their inhibitors in different cell lines could play a role.
Accordingly, the varying ability of different death stimuli to regulate
the expression levels of individual cathepsins or their inhibitors could
explain the difference in response to different stimuli. For example,
adriamycin and etoposide are known to enhance the expression ofcathepsin D via the activation of p53[55]. Alternatively, other signaling
pathways induced by various stimuli may co-operate with speciﬁc
cathepsins.
2.2. Signaling to lysosomal membrane permeabilization
Lysosomal membrane permeabilization followed by the release of
lysosomal contents, especially cathepsins, to the cytosol is considered
to be the key activation step of the lysosomal death pathway. However,
aside from the direct membrane-disruptive stimuli described above,
the signaling pathways leading to LMP are only beginning to emerge
(Fig. 2).
One of the best-studied mechanisms is the signaling from the TNF-
receptor 1 although the clariﬁcation of this signaling pathway to LMP
has been greatly complicated bywidely different responses in different
target cells.
In summary, TNF can either induce caspase-dependent or
-independent permeabilization of lysosomal membranes depending
on cellular context [23,56,57]. In addition, the TNF-related ligands
FasL, TRAIL and TWEAK have also all been associated with caspase-
independent cell death [18,19,23,43,56,58]. Pharmacological and
genetic studies indicate that the caspase-mediated pathway leading
from TNF to LMP is dependent on caspases-8 and -9, although
activation of caspase-9 differs widely between human and murine
cells [23,59–61]. The link between caspases and LMP is as yet
unknown, and although TNF-induced caspase-8-mediated cleavage
of Bid has been suggested to contribute to LMP, these ﬁndings could
not be veriﬁed by TNF-induced LMP in Bid-deﬁcient immortalized
MEFs [59,61]. Bid has furthermore been suggested to be a target for
cathepsins in lysosomal death pathways implicating Bid downstream,
rather than upstream, of the LMP, although this role for Bid has been
questioned by work done in a Bid- and cystatin B-deﬁcient mouse
model of progressive myoclonus epilepsy [36,62].
TNF also stimulates sphingomyelin breakdown to phosphorylcho-
line and ceramide by activating neutral sphingomyelinase (SMase) at
the plasma membrane and acid SMase (aSMase) in the lysosomal
compartment [63]. Both events have been implicated in TNF-induced
cell death pathways, but so far only neutral SMase has been connected
Fig. 2. Schematic presentation of lysosomal involvement in cell death signaling. Numerous cytotoxic treatments either directly or indirectly induce permeabilization of the lysosomal
membranes (LMP), resulting in the release of lysosomal content into the cytosol. Here, e.g. lysosomal proteases, the cathepsins, can mediate cell death either in a caspase-
independent manner or by inducing release of apoptogenic factors from the mitochondria followed by caspase activation (please refer to the text for details). Stimuli that induce LMP
are printed in red. Proteins that modulate the lysosomal death pathways are printed in blue.
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Studies based on FAN deﬁcient immortalized MEFs as well as human
ﬁbroblasts expressing a dominant negative form of FAN have shown
that FAN does not only mediate TNF-induced ceramide production,
but also contributes to the caspase-8 processing and cell death. Since
the TNF-induced LMP in murine hepatocytes depends on caspase-8,
its reduced processing may explain the reduced LMP in TNF-treated
hepatocytes expressing dominant negative FAN [8,59]. The role of
ceramide and its metabolites can, however, not be ruled out. Their role
in TNF-induced death signaling is supported by the reduced TNF and
Fas-induced hepatotoxicity in mice deﬁcient for aSMase, which is
activated downstream of caspase-8[65,66]. Especially sphingosine
that is generated from ceramide in a reaction catalyzed by the
lysosomal enzyme acid ceramidase is a tempting candidate, as it,
contrary to ceramide, can act as a detergent, directly destabilizing the
lysosomal membrane [67,68]. In addition to increasing the generation
of the sphingosine precursor, ceramide, by activating SMases, TNF
regulates sphingosine levels also by cathepsin B-mediated down-
regulation of sphingosine kinase-1, an enzyme that converts the pro-apoptotic sphingosine to an anti-apoptotic sphingosine-1-phosphate
[69]. This activity of cathepsin B could result in the accumulation of
sphingosine in the lysosomes and may thus, at least partially, explain
the requirement of cathepsin B for an efﬁcient LMP in TNF-treated
hepatocytes [68].
TNF can also trigger LMP and cell death in the presence of caspase
inhibitors. This pathway is independent of caspase-8, but requires
the death domain-containing receptor interacting protein-1 (RIP-1)
and involves the generation of reactive oxygen species [19,38,70,71]
(T. Farkas and M. Jäättelä, unpublished data). Oxidative stress can,
together with intralysosomal iron, generate oxygen radicals through
a Fenton-type chemistry and thereby may cause oxidation of
lysosomal membrane lipids, resulting in the destabilization of the
membrane and the release of the lysosomal content [72,73]. The
molecular links between RIP-1, oxidative stress and LMP are, however,
still missing.
The induction of cell death by several classic apoptosis inducers
(e.g. p53, etoposide and staurosporine) also involves LMP followed by
cathepsin-dependent mitochondrial membrane permeabilization
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LMP remain to be revealed.
2.3. Crosstalk between lysosomes and mitochondria
The cytotoxic effects of LMP often rely, at least partially, on the
activation of the mitochondrial death pathway (Fig. 2). An elegant
microinjection study has demonstrated that when localized to the
cytosol, a single lysosomal hydrolase, cathepsin D, is sufﬁcient to
trigger the mitochondrial outer membrane permeabilization and
apoptosis in human ﬁbroblasts at cellular doses corresponding to half
of the total cellular cathepsin D activity [75]. Cathepsin D is, however,
not sufﬁcient to trigger cell death in all models involving LMP. Other
well-documented mediators of LMP-triggered cell death include
cysteine cathepsins B and L as well as reactive oxygen species [76].
It should, however, be emphasized that possible roles for other
lysosomal hydrolases, lysosome-derived secondmessengers and LMP-
induced acidiﬁcation of the cytosol are still open, not least so because
of lack of research focusing on these questions. One of the links
between cathepsins and mitochondrial membrane permeabilization
may be Bid, a pro-apoptotic BH3-only protein of the Bcl-2 family that
can be processed and activated by several cysteine cathepsins at
cytosolic pH [36]. Along these lines, the aspartic Cathepsin D has been
suggested to cleave and activate Bid in the acidic environment of the
endolysosomal compartment following TNF receptor-1 (TNF-R1)
internalization [77,78]. According to this model, the endocytosis of
the ligand-activated TNF-R1 results in acid sphingomyelinase-
mediated generation of ceramide, which then binds to the inactive
cathepsin D and activates it via autocatalytic processing [79].
Cathepsin D may also activate Bax in a Bid-independent manner as
demonstrated in staurosporine-treated T cells [51]. Furthermore, in
ﬁbroblasts treated with ciproﬂoxacine, LMP triggers mitochondrial
membrane permeabilization through a Bid-independent activation of
Bax and Bak [39]. In this model system the Bax activation is
independent of cathepsin D, but relies instead on reactive oxygen
species. It should be noted that ciproﬂoxacine-induced mitochondrial
membrane permeabilization is not fully inhibited in cells lacking both
Bax and Bak. The alternative mechanisms connecting LMP to the
mitochondrial membrane permeabilization may include the direct
effects of reactive oxygen species and/or lipid mediators such as
arachidonic acid that can be generated in a cathepsin B-dependent
manner [76].
2.4. Mitochondrion-independent lysosomal death pathways
Importantly, the lethal effects of LMP and cytosolic cathepsins are
not limited to the activation of the intrinsic apoptosis pathway. In small
cell lung cancer cells treated with microtubule stabilizing drugs
(paclitaxel, epothilone B and discodermolide), LMP occurs early in the
death process and cysteine cathepsins mediate micronucleation and
cell death in a caspase-independent manner [46]. In TNF-treated
human carcinoma cell lines LMP occurs downstream of mitochondrial
outer membrane permeabilization [23,26,61]. However, the inhibition
of cysteine cathepsin activity or expression confers signiﬁcant
protection against TNF-induced cell death without signiﬁcantly
inhibiting the effector caspase activation. Furthermore, cathepsin B is
responsible for apoptosis-like changes, such as chromatin condensa-
tion, phosphatidylserine exposure and plasmamembrane blebbing, in
the absence of caspase activity in TNF-treated murine WEHI-S
ﬁbrosarcoma cells [23]. Furthermore, the depletion of heat shock
protein 70 (Hsp70) in various human cancer cells [40] as well as
supraoptimal activation of T cells [80] triggers LMP and cathepsin-
mediated apoptosis-like cell death without the activation of the
intrinsic apoptosis pathway. In line with these data, cathepsin B can
induce nuclear apoptosis in isolated nuclei [81]. Thus, cathepsins
appear to carry both the ability to act as initiator- as well as effectorproteases of programmed cell death depending on the stimulus and
the cellular context. Especially their ability to mediate cell death in
cancer cells, where the mitochondrial death pathway is blocked for
example due to overexpression of Bcl-2, raises hopes that treatments
inducing LMP may prove effective in treatment of cancers that are
resistant to inducers of classic apoptosis [22,40]. This idea is further
supported by data showing that immortalization and transformation
can sensitize cells to the lysosomal cell death [8,23,53,82]. One should
be aware though, that the activity of cysteine proteases is not always
positively correlated to cell death. It has, for instance, been shown that
inhibitors of Cathepsin B such as CA-074 and E-64 lead to human
neuroblastoma cell death dependent on caspases [83]. As such, the
present understanding of the roles of cathepsins in programmed cell
death appears to be context- and/or cell type-dependent, which could
be attributed to functional redundancy of the cathepsins. A compli-
mentary explanation for some of the discrepancies observed in the
literature could be the site of action of the cathepsins as these
proteases can act both intracellularly as well as extracellularly—this
distinction becomes particularly important in cancer where cysteine
cathepsins serve distinct pro-oncogenic extracellular roles, but in
which one might also want to exploit their cytotoxic intracellular
capabilities [9,10].
3. Transformation-induced changes in the lysosomal compartment
Transformation of cells leads to a series of changes in the
lysosomal compartment which ultimately lead to increases in
lysosomal volume and total protease activity as well as enhanced
secretion of lysosomal proteases [9,84,85]. Studies on the lysosomal
proteases, the cathepsins, have revealed that transformation induces
marked changes in the trafﬁcking and subcellular localization of the
cathepsins B, D and L [86–90]. These changes in the lysosomal
compartment become pro-oncogenic when the enhanced secretion of
cysteine cathepsins initiate proteolytic pathways that increase
neoplastic progression [9]. Indeed, particularly cathepsin B is recog-
nized as an important contributor to tumor angiogenesis and the
activity of this protease appears to be positively correlated with the
metastatic potential of human pancreatic cancer [85]. However, also
cathepsin S has been implicated in angiogenesis as a recent study on
cathepsin S knockout mice demonstrated that this cathepsin can act
as an enhancer of angiogenesis associated with wound healing in the
skin [91].
Perhaps the most convincing evidence for the involvement of
cathepsins in oncogenesis, however, come from mouse models of
multistage carcinogenesis [92]. In a model of pancreatic islet
tumorigenesis established by D. Hanahan [93], J.A. Joyce and co-
workers proﬁled cysteine cathepsin expression and activity and found
an elevation of cysteine cathepsin activity during tumor development,
which was important for tumor angiogenesis, cell proliferation, tumor
growth, and tumor invasion [92]. Further work from the group of J.A.
Joyce has elaborated on these ﬁndings and deﬁned distinct roles for a
subset of the cysteine cathepsins (B, L and S) in the same model of
multistage tumorigenesis [94]. Based on null-mutations of the
cathepsins B, L, S and C it was shown that deﬁciency of cathepsins B
or S impaired tumor formation and angiogenesis, whereas cathepsin B
or L knockouts impeded cell proliferation and tumor growth. The
absence of either cathepsin B, L or S impaired tumor invasion.
Interestingly, the inhibition of cysteine cathepsin activity in this model
using a membrane-permeable, pan-cathepsin-inhibitor, JPM-Oet,
impaired angiogenic switching in progenitor lesions, as well as
tumor growth, vascularity, and invasiveness and was later shown
also to enhance chemotherapy regimens [92,95]. This is particularly
interesting as lysosomal proteases, most notably cathepsin B, has also
been implicated in tumor cell death programs (an overview is
provided in Table 1) and is considered a possible chink in the armor
which protects tumor cells against death.
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transformation-induced changes in the lysosomal compartment may
serve anti-tumorigenic roles is in the context of induction of cell
death. Even though cancer cells may have several blocks in their
normal apoptotic cascades, tumor cell death may still be initiated via
activation of the lysosomal compartment. Particularly during early
stages of tumorigenesis, cancer cells are sensitized to numerous death
stimuli and often undergo spontaneous cell death, possibly due to
activation of oncogenes such as Myc and Ras, which can be sufﬁcient
to trigger cell death on their own or can sensitize the emerging cancer
cells to various cytotoxic drugs or death-receptor activation [96]. In
line with this, it has recently been shown that spontaneous
immortalization sensitizes murine embryonic ﬁbroblasts (MEFs) to a
cysteine cathepsin-mediated lysosomal death pathway [53]. In this
study, the susceptibility of wild-type MEFs to TNF mediated
cytotoxicity increased more than 1000-fold upon immortalization,
whereas immortalized MEFs deﬁcient for cathepsin B retained the
resistant phenotype of primary cells. In this model, the lack of another
cysteine cathepsin, cathepsin L, also provided resistance to the
sensitizing effect of immortalization to TNF, whereas lack of cathepsin
D and caspase-3 had no effect on the TNF-sensitivity of the
immortalized MEFs. Importantly, further oncogene-driven transfor-
mation of the immortalized MEFs was associated with a several-fold
increase in cathepsin expression and additional sensitization to TNF
and chemotherapeutic agents as well as decreased levels of LAMP-1
and –2 [53,128]. Importantly, in human cancer cell models, K-ras and
erbB2 elicit a similar activation of cysteine cathepsins and cathepsin-
dependent downregulation of LAMPs. The sensitization to various
lysosome-destabilizing drugs witnessed in these models most likely
occur as a consequence of the cathepsin-mediated loss of the LAMPs
as RNAi of either LAMP-1 or -2 is sufﬁcient to sensitize the cells to
lysosomal destabilization [53,128].
4. Cancer cell defenses against anti-tumorigenic lysosomal changes
Given the potential fatal outcome of lysosomal membrane per-
meabilization, it is not surprising that cells have developed numerous
strategies to counteract it—either by inhibiting the lysosome mem-
brane permeabilization itself or by protecting cells against the acid
hydrolases leaking to the cytosol as a consequence of lysosomal
rupture. This also holds true for cancer cells whose lysosomal
compartment is particularly prone to destabilizing events [53].
4.1. Intracellular protease inhibitors
In the event of release of lysosomal proteases to the cytosol,
cytosolic protease inhibitors present a bulwark against its deleterious
consequences. When it comes to cancer, the best characterized
intracellular lysosomal protease inhibitors are probably the squamous
cell carcinoma antigens (SCCA) 1 and 2. These are tumor-associated
proteins of squamous cell carcinomas of various organs and have been
classiﬁed as serine protease inhibitors (serpin B3 and B4)whose levels
are widely used for the diagnosis and management of diverse
squamous cell carcinomas [97]. SCCA 1 and 2 are capable of inhibiting
a variety of proteases including many of lysosomal origin such as
cathepsins G, S, L and K and their inhibitory functions have been
shown to confer tumor cell death resistance towards different
apoptotic stimuli such as TNF and the activity of IL-2 activated NK-
cells [97,98].
Whereas no endogenous inhibitors of cathepsin D are known,
cysteine cathepsins can also be effectively inhibited by several other
cytosolic protease inhibitors, i.e. cystatin A and B and serine protease
inhibitor 2A (Spi2A) which was recently found to possess potent
inhibitor activity also against several cysteine cathepsins (B, H, K, L
and V) and cathepsin G [99–101]. The importance of these inhibitors
in preventing cell death in physiological and pathological conditions isdemonstrated by cystatin B-deﬁcient mice which display increased
apoptosis of cerebellar granule cells [102]. Moreover, the expression of
Spi2A is induced upon TNF-treatment via the NF-κB pathway, and
effectively inhibits TNF-induced cytosolic cathepsin B activity and cell
death in MEFs [101,103].
Interestingly, it has just been reported that in C. elegans, the
cytosolic serine protease inhibitor (serpin)-6 can protect against both
the induction as well as the lethal effects from lysosomal injury caused
by hypo-osmotic stress as well as a variety of other lysosomal stresses,
demonstrating that protection against LMP is an evolutionarily
conserved mechanism [33].
4.2. PI3K-signalling
Among its many other functions, phosphatidylinositol 3-kinase
(PI3K) has been reported to protect lysosomes against destabilization.
Inhibition of PI3K in human vascular endothelial cells induces the
release of cathepsin B to the cytosol arguing for a rather direct role of
PI3K in preserving lysosomal membrane integrity [44]. Furthermore,
PI3K inhibitors sensitize the cells to the TNF- and interleukin-1-
induced lysosomal death pathways [44]. Thus, PI3K, which is
commonly activated in human cancer cells, may also contribute to
lysosomal stability of tumor cells and thereby increase their cell death
resistance.
4.3. Heat shock protein 70
Whereas the role of PI3K on the stability of tumor cell lysosomes at
this point remains speculative, recent data advocate for a deﬁnite role
for Heat shock protein (Hsp) 70 as a guardian of lysosomal integrity.
This work has mainly been done in tumor cells, which also often
demonstrate a localization of Hsp70 on the plasma membrane as well
as in the endolysosomal compartment [40,104–108].
Apart from its anti-apoptotic abilities as a consequence of being a
molecular chaperone, i.e. facilitating protein folding under otherwise
denaturing conditions, Hsp70 is also able to enhance survival of cells
in the face of a wide variety of stimuli including death-inducing
cytokines and classical chemotherapeutic drugs [109–116].
A role for Hsp70 as an essential factor for cancer cell survival was
ﬁrst presented in a report by Wei et al., in a depletion-study of Hsp70
in cancer cells [117]. This role has since been substantiated in a series
of experiments in which adenoviral antisense-mediated depletion of
Hsp70 triggers a tumor cell-speciﬁc lysosomal death program [22,40].
In vivo studies utilizing orthotopic xenografts of glioblastoma and
breast carcinomas as well as sub-cutaneous xenografts of colon-
carcinoma in immunodeﬁcient mice has further demonstrated the
anti-cancer potential of Hsp70 depletion, as the tumors of mice
receiving locoregional application of the adenoviral construct showed
intracellular release of cathepsins, tumor cell death and recruitment of
macrophages [118]. These studies clearly demonstrate the depen-
dence of some tumors upon the presence of Hsp70, although parts of
the observed cytotoxicity probably stem from the ability of the
antisense construct to also target other Hsp70-family members such
as Hsp70-2 [119–121]. Importantly, the cell death induced by the
depletion of Hsp70 was not dependent on caspases, but was
characterized by the release of cathepsins to the cytosol and inhibition
of these provided signiﬁcant cytoprotection [22,40], which suggests
that parts of the potent cytoprotective effect of Hsp70 are due to
stabilization of lysosomalmembranes. Further evidence for this comes
from studies which show that exogenous Hsp70 effectively inhibits
lysosomal destabilization induced by various stresses [40,61,107] and
that mice deﬁcient for Hsp70 suffer from pancreatitis caused by the
leakage of lysosomal proteases into the cytosol [122].
This cytoprotective mechanism of Hsp70, which many cancer cells
seem to have adapted, i.e. the translocation of Hsp70 to the
endolysosomal compartment [40] may have unfortunate consequences
Fig. 3. Current and theoretical approaches to target and exploit the transformation-induced changes of the lysosomal compartment. During transformation several changes occur in
the lysosomal compartment—amongst these increases in overall cathepsin activity. As lysosomal proteases both serve pro- as well as anti-oncogenic roles during tumor development
via their extra- and intracellular functions, respectively, different approaches can be consideredwhen it comes to target these for anti-cancer therapy. The global inhibition of cysteine
cathepsins in a mouse model of pancreatic cancer has veriﬁed the feasibility of an “inhibit-all” approach [92] but in this way the pro-cell death functions of cathepsins are of course
also inhibited. Alternatively, but yet only theoretically, the trafﬁcking or secretion of lysosomes would present an obvious target. In this model, the inhibition of e.g. the secretory
pathway would eliminate the extracellular pro-oncogenic properties of lysosomal proteases while increasing the intracellular amount available for cell death execution. As the
lysosomal compartment furthermore becomes increasingly sensitive to disruptive stimuli upon transformation, thismight render the cancer cells evenmore susceptible to lysosome-
targeting anti-cancer agents such as Siramesine [125]. Additionally, the sheer bulk of “trapped” lysosomes might be enough to provide the amount of lysosomal protease release
necessary for efﬁcient cancer cell death to occur.
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tumors show localization of Hsp70 on the plasma membrane surface
[106] —an area which is directly connected with the endolysosomal
compartment via endocytic and secretory events. Whereas the
endolysosomal localized Hsp70 offers cytoprotection, the surface-
exposed Hsp70 can act as a recognition structure for natural killer
(NK)cells, stimulating their proliferation and cytolytic activity [105,123].
As the endolysosomal membranes and plasma membranes are
constantly interchanged, the presence of Hsp70 on the surface of cancer
cells could be an “unfortunate” consequence of two events that promote
tumor progression; the secretion of cathepsins, which promotes
invasion and angiogenesis, and the localization of Hsp70 on the
lysosomal membranes, which prevents accidental release of cysteine
cathepsins to the cytosol and ensuing cell death [92,124]. As such, these
changesmight all be parts of an ancient stress response triggered by the
process of oncogenesis for better and for worse, although this remains
speculative.
Whatever the primary cause of Hsp70 localization to the
lysosomal compartment may be, the molecular mechanism for the
cytoprotection this localization confers has so far remained elu-
sive, but could provide several interesting targets for future cancer
therapy.
5. Perspectives
The study of lysosomal changes in tumour progression and
treatment is still very young, but the recent great advances in this
ﬁeld promise rapid progress in the near future. In this regard it is
interesting that drug delivery should be very practicable for drugs
targeting the lysosomes, as this compartment can be reached through
the endocytic machinery. Other approaches targeting the lysosomes
could include drugs targeting the already altered lysosomal trafﬁcking
pathways occurring in cancer cells, as this might give rise to
populations of lysosomes even more prone to membrane rupture
(Fig. 3).
Drug screens to identify molecules that induce lysosomal rupture
may also prove effective in ﬁnding new compounds that activate thelysosomal death pathway. Interestingly, in a recent small molecule
library screen, more than 50% of the compounds that induce
signiﬁcant cell death in p53-null cells trigger LMP and cathepsin-
mediated killing of tumor cells [52]. Importantly, promising anti-
cancer compounds targeting lysosomal integrity are also appearing
such as the sigma-2 receptor ligand Siramesine [47,125].
At this point, the rapid advances in our understanding of cancer-
associated changes in the lysosomes prompt additional investments in
how to best target the pro- and anti-oncogenic potential of this
complex compartment. In this regard, future elucidation of the
molecular mechanisms controlling lysosomal membrane stability
will hopefully present novel targets for cancer therapy.
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